Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid Bechtold

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|December 4, 2013
Efficient processes for protein expression using recombinant baculovirus particlesHeike Cremer, Ingrid Bechtold, Marion Mahnke, et al.
Science Advances|February 8, 2023
Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevanceSara G Danielli, Ermelinda Porpiglia, Andrea J De Micheli, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 29, 2025
EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitorsBernhard Haller, Günther H S Richter, Marco Wachtel, et al.
Nature Communications|August 21, 2025
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic targetWillemijn Breunis, Eva Brack, Anna C Ehlers, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|December 4, 2013
Efficient processes for protein expression using recombinant baculovirus particlesHeike Cremer, Ingrid Bechtold, Marion Mahnke, et al.
Science Advances|February 8, 2023
Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevanceSara G Danielli, Ermelinda Porpiglia, Andrea J De Micheli, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 29, 2025
EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitorsBernhard Haller, Günther H S Richter, Marco Wachtel, et al.
Nature Communications|August 21, 2025
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic targetWillemijn Breunis, Eva Brack, Anna C Ehlers, et al.
Pageof 1